CN BIO INNOVATIONS
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B... ®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market.
CN BIO INNOVATIONS
Industry:
Biopharma Biotechnology Health Care Life Science Medical Medical Device
Founded:
2009-01-01
Address:
Welwyn Garden City, Hertford, United Kingdom
Country:
United Kingdom
Website Url:
http://www.cn-bio.com
Total Employee:
11+
Status:
Active
Contact:
44 18 6530 9600
Email Addresses:
[email protected]
Total Funding:
23.53 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
GrayBella Capital
GrayBella Capital investment in Series B - CN Bio Innovations
Innovate UK
Innovate UK investment in Grant - CN Bio Innovations
CN Innovations
CN Innovations investment in Venture Round - CN Bio Innovations
CITIC Securities
CITIC Securities investment in Venture Round - CN Bio Innovations
Innovate UK
Innovate UK investment in Grant - CN Bio Innovations
CN Innovations
CN Innovations investment in Seed Round - CN Bio Innovations
Official Site Inspections
http://www.cn-bio.com Semrush global rank: 4.54 M Semrush visits lastest month: 2.32 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "CN Bio Innovations"
CN Bio | Organ-on-a-chip company | Human Drug Discovery
CN Bio is a world leading organ-on-a-chip company. We empower you to transform drug discovery with our predictive human organ models.See details»
CN Bio - Crunchbase Company Profile & Funding
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human …See details»
CN-Bio Company Profile 2024: Valuation, Funding
CN-Bio General Information Description. Manufacturer of a microphysiological system intended for advancing biomedical research and drug development. The company's device replicates the microenvironment of human organs and …See details»
CN Bio - Funding, Financials, Valuation & Investors - Crunchbase
Venture Round - CN Bio . Hao Fang: CITIC Securities . Yes: Venture Round - CN Bio . Hao Fang: Innovate UK . Yes: Grant - CN Bio — CN Innovations . Yes: Seed Round - CN Bio . Winston …See details»
CN Bio Innovations - Human Relevant Science
CN Bio is also developing organ-on-chip models for specific diseases including non-alcoholic steatohepatitis and Hepatitis B. CN Bio is a co-recipient with MIT of a $26M US Federal …See details»
CN Bio raises $21 million; the OOC company will fund …
Apr 23, 2024 Charles Chong, Managing Director, CN Innovations, added: “We are encouraged by CN Bio’s ongoing success and, in particular, the team’s achievements over the past years, during which conditions have been difficult …See details»
CN Bio | Lab Manager
CN Bio CN Bio develops organ-on-a-chip technologies that mimic human physiology for drug discovery and development. Their cutting-edge platforms accelerate the development of …See details»
CN Bio Raises $21 Million USD in First Close of Series B Investment …
CAMBRIDGE, England, April 23, 2024--CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first …See details»
CN Bio Innovations - Org Chart, Teams, Culture & Jobs - The Org
CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. Industries. Biotechnology, Health Care +2. …See details»
CN Bio Company Profile - Office Locations, Competitors, Revenue …
CN Bio has 5 employees across 2 locations, $11.51 m in total funding, and £2.13 m in annual revenue in FY 2022. See insights on CN Bio including office locations, competitors, revenue, …See details»
CN Bio raises $21 million USD in first close of Series B investment …
Apr 23, 2024 Image Credit: CN Bio. CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first …See details»
CN Bio raises $21 million USD in first close of Series B investment ...
Apr 23, 2024 Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively Investment will expand product development and scaling of the …See details»
CN Bio raises $21 million to scale up organ-on-a-chip technology
Apr 23, 2024 CN Bio has taken key steps to build a team with extensive industry expertise and robust networks across the industry, with a longstanding track record of success,” said …See details»
Meet the CN Bio team – Oliver Culley
Nov 18, 2024 CN Bio’s targets and opportunities are described clearly through regular one-to-one, team-centric, and company-wide meetings. I am able to discuss my responsibilities, …See details»
CN Bio Expands Service Offering to Support Oncology Drug …
Oct 5, 2021 Dr David Hughes, CEO, CN Bio, commented: “Ninety percent of drugs entering phase 1 trials fail, often due to a lack of efficacy, and consequently resulting in billions wasted …See details»
LifeNet Health LifeSciences partners with CN Bio to set a new …
Sep 6, 2023 LifeNet Health cells have consistently demonstrated higher success rates in CN Bio studies, according to Tomasz Kostrzewski, PhD, the company's Chief Scientific Officer. …See details»
Life Sciences Jobs | Biotech Careers | Cambridge UK
I joined CN Bio in 2018 and have been fortunate to witness the company’s impressive growth firsthand. It’s been inspiring to see the core values, which resonate with my own, remain …See details»
Leadership Team | Who We Are | About CN | cn.ca
Tracy Robinson was appointed President and Chief Executive Officer of CN on February 28, 2022 and is responsible for CN’s strategic direction and leadership. Read more » Download the full …See details»
In vitro contract research services - CN Bio
©2024 CN Bio Innovations Ltd Registered No. 06517359. VAT No. GB978184563. Latest news. Meet the CN Bio team – Oliver Culley November 18, 2024; CN Bio launches PhysioMimix …See details»